Pulmonary Embolism, Advanced VTE Therapy, and Vena Cava Filters

54.1Definition and presentation

Acute pulmonary embolism (PE) is a spectrum of venous thromboembolic disease ranging from an asymptomatic presentation to obstructive shock. The condition presents with physiologic severity defined by hemodynamic reserve and right-ventricular response rather than anatomic clot burden. Overall in-hospital mortality ranges from 1% in low-risk presentations to 15% or higher in hemodynamically unstable cases, reaching 58% in patients presenting with cardiogenic shock or sustained hypotension ESC 2019 · ICOPER 1999.

Presenting features define the severity tier:

• High-risk: shock or persistent hypotension.
• Intermediate-high-risk: normotension with both right-ventricular dysfunction and elevated cardiac biomarkers.
• Intermediate-low-risk: normotension with one positive risk marker.
• Low-risk: normotension with no right-ventricular dysfunction and negative biomarkers.

54.2Diagnosis and imaging

Diagnosis follows a structured pretest probability and D-dimer pathway to avoid unnecessary imaging. The Wells score (<= 4 'PE unlikely', > 4 'PE likely') or revised Geneva score stratifies outpatient and emergency-department probability Geneva 2006 · Wells 2000. The Pulmonary Embolism Rule-out Criteria (PERC) rule out PE in very-low-probability populations without D-dimer testing PERC 2008. For appropriate populations, an age-adjusted D-dimer threshold (age x 10 mcg/L in patients over 50 years) or the YEARS algorithm safely rules out PE YEARS 2017 · ADJUST-PE 2014.

Computed tomography pulmonary angiography (CTPA) on helical scanners is the imaging reference standard for confirmed-positive pretest probability or positive D-dimer ESC 2019 · PIOPED II 2006. Ventilation-perfusion (V/Q) scanning is the preferred alternative when CTPA is unsafe or undesirable, principally in pregnancy, severe contrast allergy, or renal impairment PIOPED 1990.

54.3Severity classification and risk stratification

Confirmed PE requires immediate prognostic stratification to govern disposition. The Pulmonary Embolism Severity Index (PESI) and simplified PESI (sPESI) stratify 30-day mortality. The sPESI identifies low-risk patients (30-day mortality < 2%) using six binary criteria: age > 80 years, history of cancer, chronic cardiopulmonary disease, heart rate >= 110 beats per minute, systolic blood pressure < 100 mmHg, and oxygen saturation < 90% sPESI 2010 · PESI 2005.

The Hestia criteria operationalize early discharge and outpatient management eligibility by excluding patients with hemodynamic instability, high oxygen requirements, severe pain, bleeding risks, or social isolation HESTIA 2011. For normotensive patients outside the low-risk category, the Bova score divides intermediate-risk patients into three complication tiers using systolic blood pressure, heart rate, troponin, and right-ventricular imaging ESC 2019 · Bova · 2014.

54.4Treatment decision and disposition

Management of acute PE turns on physiologic severity and bleeding risk, distinguishing medical observation from reperfusion therapies. Hemodynamically unstable patients require immediate advanced therapy, whereas stable patients with right-ventricular strain require disciplined multidisciplinary assessment. A Pulmonary Embolism Response Team (PERT) operationalizes triage for intermediate-high-risk and high-risk cases, combining medical, surgical, and interventional expertise to select the appropriate reperfusion modality PERT Consortium 2016.

1. Decide outpatient management versus hospital admission based on Hestia criteria and sPESI score.
2. Initiate therapeutic anticoagulation universally, barring absolute contraindications.
3. Decide systemic thrombolysis suitability for high-risk (unstable) PE after reviewing bleeding contraindications.
4. Decide catheter-directed therapy suitability for intermediate-high-risk PE with right-ventricular strain.
5. Decide vena cava filter placement for patients with absolute contraindications to anticoagulation or recurrent disease on therapy.

54.5Anticoagulation and vena cava filters

When clinical pretest probability of pulmonary embolism is high, start therapeutic anticoagulation immediately, before confirmatory imaging, unless bleeding risk is prohibitive ESC 2019. Direct oral anticoagulants (DOACs) are first-line therapy for most eligible patients. In the EINSTEIN-PE trial, rivaroxaban demonstrated non-inferiority for recurrent venous thromboembolism and a significant reduction in major bleeding compared with an enoxaparin and vitamin-K antagonist strategy EINSTEIN-PE 2012. The single-drug rivaroxaban regimen uses a 15 mg twice-daily oral lead-in for 3 weeks before transitioning to maintenance dosing. Dabigatran and edoxaban do not have a single-drug pathway and require a 5 to 10 day parenteral heparin lead-in before the oral agent starts. DOACs are contraindicated in patients with mechanical heart valves, triple-positive antiphospholipid syndrome, and severe renal impairment. All PE requires at least 3 months of therapeutic anticoagulation. PE provoked by a major transient or reversible risk factor stops at 3 months. Unprovoked PE, recurrent VTE, or active cancer warrants extended or indefinite anticoagulation with periodic bleeding-risk reassessment; reduced-dose apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily are options for extended treatment.

Inferior vena cava filters do not augment effective anticoagulation. The PREPIC and PREPIC-2 trials demonstrated that adding a filter to anticoagulation does not reduce overall mortality and increases the long-term risk of recurrent deep vein thrombosis PREPIC-2 2015 · PREPIC 1998. Vena cava filters are indicated solely when therapeutic anticoagulation is absolutely contraindicated, when recurrent pulmonary embolism occurs despite therapeutic anticoagulation, or in highly selected high-risk peri-operative scenarios. Every retrievable filter requires a scheduled retrieval plan at the time of insertion, tracked as a clinical quality metric PRESERVE 2023.

54.6Systemic thrombolysis and advanced therapies

Systemic thrombolysis provides rapid relief of pulmonary vascular obstruction in high-risk PE. The standard agent is alteplase (rt-PA), 100 mg IV over 2 hours; an accelerated 0.6 mg/kg bolus over 15 minutes to a maximum of 50 mg is the alternative in cardiac arrest or peri-arrest ESC 2019 · AHA 2011. Streptokinase and urokinase are legacy alternatives, given either as a loading dose plus a 12 to 24 hour infusion or as an accelerated 2-hour course. Meta-analyses demonstrate that systemic thrombolysis reduces all-cause mortality (2.2% versus 3.9%) and recurrent PE compared with heparin alone, but increases major bleeding (9.2% versus 3.4%) and intracranial hemorrhage (1.5% versus 0.2%) Chatterjee 2014 · Marti 2014. For intermediate-high-risk PE, the PEITHO trial showed tenecteplase reduces hemodynamic decompensation or death at day 7 (2.6% versus 5.6%) but increases major extracranial bleeding (6.3% versus 1.2%) and intracranial hemorrhage (2.0% versus 0.2%) without improving long-term mortality or right-ventricular function PEITHO 2014 · PEITHO Long-term 2017. Absolute contraindications include recent intracranial bleeding, recent neurosurgery, an intracranial mass, and active bleeding. Relative contraindications, including recent major surgery or trauma, active or recent bleeding, current therapeutic anticoagulation, and pregnancy, shift the balance toward catheter-directed or surgical therapy.

Catheter-directed therapies and large-bore mechanical thrombectomy offer right-ventricular decompression with reduced or zero systemic thrombolytic exposure . Ultrasound-assisted catheter-directed thrombolysis uses reduced-dose alteplase (ULTIMA, SEATTLE II) to reduce the right-ventricle-to-left-ventricle ratio and pulmonary artery pressures with a very low intracranial hemorrhage risk ULTIMA 2014 · SEATTLE II 2015. Large-bore mechanical thrombectomy provides a purely mechanical option. The FLARE trial (FlowTriever) reported a right-ventricular ratio reduction of 0.25 within 48 hours, and the EXTRACT-PE trial (Indigo) reported a 0.4 reduction, both with major bleeding rates near 2% and no intracranial hemorrhage EXTRACT-PE 2021 · FLARE 2019. Real-world registry data support these surrogate endpoints FlowTriever Registry 2023.

54.7Areas of controversy

The mortality benefit of catheter-directed therapy and large-bore mechanical thrombectomy over standard anticoagulation remains unproven by randomized trials; widespread adoption relies on surrogate hemodynamic endpoints rather than survival outcomes . The clinical value of early advanced reperfusion in preventing long-term chronic thromboembolic pulmonary hypertension in intermediate-risk PE is not definitively established PEITHO Long-term 2017. Reduced-dose systemic thrombolysis protocols remain an active area of investigation seeking to decouple hemodynamic improvement from catastrophic bleeding.